Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer

In recent years, studies have explored different combinations of immunotherapy and chemotherapy. The rationale behind these is the improved survival outcomes of new immunologic therapies used in first-line-treatment of advanced non-small cell lung cancer. Moreover, for the most-studied combinations...

Full description

Bibliographic Details

Published in:	World journal of clinical oncology Vol. 12; no. 12; pp. 1182 - 1192
Main Authors:	Sereno, María, Higuera, Oliver, Cruz Castellanos, Patricia, Falagan, Sandra, Mielgo-Rubio, Xabier, Trujillo-Reyes, Juan Carlos, Couñago, Felipe
Format:	Journal Article
Language:	English
Published:	United States Baishideng Publishing Group Inc 24-12-2021
Subjects:	Minireviews Anti- programmed cell death protein Non-small cell lung cancer Combo anti-CTLA-4 anti-TIGIT Immunotherapy combinations Anti-programmed cell death ligand 1
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!